This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data With Sanofi’s SAR3419 In Diffuse Large B-Cell Lymphoma

Stocks in this article: IMGN

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of favorable clinical findings with SAR3419 (coltuximab ravtansine) from the STARLYTE Phase II trial in diffuse large B-cell lymphoma (DLBCL). SAR3419 is a CD19-targeting ADC developed by ImmunoGen and licensed to Sanofi as part of a broader collaboration between the companies. The study results were reported in an oral abstract session at the American Society of Clinical Oncology (ASCO) 50 th Annual Meeting being held in Chicago, IL; they were also selected for Best of ASCO (abstract #8506).

In the data presented today, study investigators reported achievement of proof of concept, with 43.9% objective response rate (ORR) for the per protocol population (patients with relapsed or relapsed/refractory disease). The primary objective of the study was to assess whether single agent SAR3419 could achieve an ORR of at least 20% in this patient population using Cheson 2007 criteria. Additionally, objective responses were reported among the patients enrolled with primary refractory disease – cancer that had not responded to first-line treatment – with a 21.4% ORR.

“SAR3419 demonstrated promising activity against previously treated DLBCL, including disease that had not responded to first-line treatment,” commented Daniel Junius, president and CEO of ImmunoGen. “We believe the unique profile of SAR3419 can make an important difference for patients with DLBCL, and potentially for other types of B-cell malignancies. These data also add to the growing body of favorable findings with ADCs using our technology.”

The STARLYTE trial is evaluating the efficacy and safety of SAR3419 used as a single agent to treat relapsed or relapsed/refractory CD19-positive DLBCL. Patients received SAR3419 at 55 mg/m 2 weekly for four weeks and then every other week until disease progression or discontinuation. Of the patients enrolled in the trial, 55 were evaluable for efficacy and 61 were evaluable for safety.

The 41 per protocol patients included 26 patients with relapsed but not refractory disease and 15 patients with disease refractory to their last treatment. Among these patients:

  • The ORR was 53.8% among the patients with relapsed disease, with 69.2% having stable disease or better. The 14 patients with objective responses included 5 patients with complete responses (CRs) and 9 patients with partial responses (PRs).
  • Among the 15 patients with disease refractory to the last treatment, the ORR was 26.7%, with 46.7% having stable disease or better. These included 1 CR and 3 PRs.

The 55 efficacy evaluable patients also included 14 individuals with primary refractory disease. Among these patients, the ORR was 21.4%, with 35.7% having stable disease or better. The objective responses reported included 1 CR as well as 2 PRs.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,399.67 +19.26 0.12%
S&P 500 1,904.01 +17.25 0.91%
NASDAQ 4,316.0740 +57.6360 1.35%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs